Medical devices industry venture financing deals in October 2020 total $1.05bn globally

23 November 2020 (Last Updated November 23rd, 2020 07:44)

Medical devices industry venture financing deals in October 2020 total $1.05bn globally

Total medical devices industry venture financing deals in October 2020 worth $1.05bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 19.6% over the previous month and a drop of 20.9% when compared with the last 12-month average, which stood at $1.33bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $582.02m. At the country level, the US topped the list in terms of deal value at $576.77m.

In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of venture financing deals activity in October 2020 was the US with 40 deals, followed by China with seven and Israel with four.

In 2020, as of the end of October 2020, medical devices venture financing deals worth $13.6bn were announced globally, marking an increase of 61.8% year on year.

Medical devices industry venture financing deals in October 2020: Top deals

The top five medical devices industry venture financing deals accounted for 46.3% of the overall value during October 2020.

The combined value of the top five medical devices venture financing deals stood at $486m, against the overall value of $1.05bn recorded for the month.

The top five medical devices industry deals of October 2020 tracked by GlobalData were:

1) CCB International Capital, China International Capital, China Renaissance Holdings, China Structural Reform Fund, CICC Capital ManagementLimited, GL Ventures, Matrix Partners China and Taikang Asset Management’s $149m venture financing of GeneCast Biotechnology

2) The $110m venture financing of Sophia Genetics by ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures

3) 8VC, Baidu Ventures, Coatue Management, D1 Capital Partners, Lux Capital, Playground Global, Refactor Capital and Sonder Capital’s $100m venture financing of Avail Medsystems

4) The $72m venture financing of Neocis by DFJ Growth Management, Fred Moll, Mithril Capital Management, Norwest Venture Partners, Section 32 and Vivo Capital

5) Asset Management Ventures, Franklin Templeton Investments, Jonathan Fielding, King River Capital, Lightspeed Ventures,Ltd., Olive Tree Capital, SteelSky Ventures and Weili Dai’s venture financing of LARK HEALTH for $55m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.